Safety, tolerability and pharmacodynamics of a novel immunomodulator, MIS416, in patients with chronic progressive multiple sclerosis
Background Preclinical studies have demonstrated that MIS416, a bacterially derived immune modulator, targets myeloid cells following systemic delivery. MIS416 stimulated myeloid cells have the capacity to regulate innate inflammation, a potential therapeutic target for progressive multiple sclerosi...
Sparad:
| Huvudupphov: | , , , |
|---|---|
| Materialtyp: | Artigo |
| Språk: | Inglês |
| Utgiven: |
SAGE Publishing
2015-05-01
|
| Serie: | Multiple Sclerosis Journal - Experimental, Translational and Clinical |
| Länkar: | https://doi.org/10.1177/2055217315583385 |
| Taggar: |
Inga taggar, Lägg till första taggen!
|